This dichotomous diagnosis, proposed by the ASCO/CAP update of 2018 [3], considers HER2-positive BC (HER3+/ISH amplified) to represent 15% of cases and the rest (85%) to be HER2-negative. This evidence concerns the gene ERBB2 and breast cancer.